Apr 23, 2002
PR Newswire - USA
People with relapsing-remitting multiple sclerosis (MS) will gain more than 20 hours in time savings -- an additional weekend per year -- from a new delivery system for COPAXONE(R) (glatiramer acetate injection) just released this week.
COPAXONE(R) just became available in a pre-filled, ready-to-use syringe. For the people in the United States with relapsing-remitting multiple sclerosis (RRMS), the innovation may mean less time and effort spent on preparing injections and more time to do the things they enjoy. In a study of people living with RRMS, more than 96 percent said the COPAXONE(R) pre-filled syringe was easier and less demanding than unmixed product.
"My whole life is about the need for speed," says Kelly "Girl" Sutton, NASCAR driver and mother of two who takes a daily injection. "Instead of spending precious minutes each day to prepare my injection, I'm finished in seconds with the new pre-filled syringe -- and off to school with the kids or to practice at the race track."
COPAXONE(R) is indicated for the treatment of relapsing-remitting MS. Its pre-filled syringe was the first one approved by the FDA in the United States. Most MS therapies require time-intensive preparation, including mixing the drug with sterile water for injection to provide the proper dose. With the new COPAXONE(R) pre-filled syringe, people living with MS will find self-injecting more manageable. The pre-filled syringe is expected to replace the previous mixable form of COPAXONE(R), and it will have the same efficacy and proven tolerability. It can be stored at room temperature for up to seven days.
Time and Motion Study
Kansas City-based Teva Neuroscience, Inc., which provides COPAXONE(R) (glatiramer acetate injection), conducted a study to quantify the time-savings potential of the new pre-filled syringe. The survey of 114 people with RRMS showed the COPAXONE(R) pre-filled syringe reduced the average (reconstituted COPAXONE(R)) preparation time from 235 seconds to 38 seconds, a time savings of more than 20 hours during the course of a year.
Because people with MS experience symptoms that can include weakness, numbness, and vision problems, eliminating the need for mixing and preparation may allow people of all ability levels to take their injection quickly and get on with the rest of their day. Some study participants even indicated that eliminating the preparation step would leave them no reason to miss a day of treatment.
"The new pre-filled syringe is about meeting people's needs for a treatment that is convenient, consistent and complete," said Larry Downey, President and Chief Executive Officer of Teva Neuroscience. "We're constantly thinking about how to make administering therapies as second-nature as flipping on a light switch."
COPAXONE(R) is indicated for the reduction in the frequency of relapses in relapsing-remitting MS. The most common side effects of COPAXONE(R) are redness, pain, swelling, itching, or a lump at the site of injection, weakness, infection, pain, nausea, joint pain, anxiety, and muscle stiffness. These reactions are usually mild and seldom require professional treatment.
Teva Pharmaceutical Industries Ltd. , headquartered in Israel, is among the top 40 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. More than 80 percent of Teva's sales are in North America and Europe. The company develops, manufactures, and markets generic and branded human pharmaceuticals and active pharmaceutical ingredients. Teva's innovative R&D focuses on developing novel drugs for diseases of the central nervous system.
Teva Neuroscience, Inc. is a subsidiary of Teva Pharmaceutical Industries Ltd. Call 1-800-887-8100 or log onto http://www.copaxone.com/ for more information about COPAXONE(R) (glatiramer acetate injection) or multiple sclerosis. Teva Neuroscience, Inc. markets COPAXONE(R).
COPAXONE(R) is a registered trademark of Teva Pharmaceutical Industries Ltd.
See additional important information at http://www.copaxone.com/pi/index.html
or call 1-800-887-8100 for electronic releases. For hardcopy releases,
please see enclosed full prescribing information.
Contact: Mandy Levings, +1-816-512-2379,or Rebecca Cisek, +1-816-512-2311, both of Fleishman-Hillard for Teva Neuroscience, Inc.
All Material Subject to Copyright